Oxidien Pharmaceuticals Selected as Winner of Buzz of BIO in Early Stage Entrepreneur Category

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company mitigating kidney stone disease by treating secondary hyperoxaluria, announced that it was recognized as a winner in Buzz of BIO, in the Early Stage Entrepreneur category following a nomination and extensive voter participation.

Helena Cowley, CEO of Oxidien Pharmaceuticals said, “We are grateful for everyone’s vote during the Buzz of BIO competition. Just being nominated demonstrates the importance of our mission and the notable progress we’ve made but winning Buzz of BIO gives us an additional boost going into BIO Investor Forum Digital where we will present this opportunity to potential new investors.”

Learn more about Oxidien Pharmaceuticals Selected as Winner of Buzz of BIO in Early Stage Entrepreneur Category.